A two dose regimen of daclizumab (Zenapax) in high-risk renal transplant recipients

被引：2
|
作者：
Millan, M [1 ]
Pavlakis, M [1 ]
Alfrey, E [1 ]
Salvatierra, O [1 ]
Dafoe, D [1 ]
Scandling, J [1 ]
机构：
[1] Stanford Univ, Adult Kidney & Kidney Pancreas Transplant Program, Stanford, CA 94305 USA
来源：
TRANSPLANTATION | 1999年 / 67卷 / 07期
关键词：
D O I：
10.1097/00007890-199904150-00339
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
311
引用
收藏
页码：S84 / S84
页数：1
相关论文
共 50 条
  • [1] Long-term safety, tolerability and efficacy of daclizumab (Zenapax®) in a two-dose regimen in liver transplant recipients
    Niemeyer, G
    Koch, M
    Light, S
    Kuse, ER
    Nashan, B
    AMERICAN JOURNAL OF TRANSPLANTATION, 2002, 2 (05) : 454 - 460
  • [2] The safety and efficacy of a two-dose daclizumab (zenapax) induction therapy in liver transplant recipients
    Eckhoff, DE
    McGuire, B
    Sellers, M
    Contreras, J
    Frenette, L
    Young, C
    Hudson, S
    Bynon, JS
    TRANSPLANTATION, 2000, 69 (09) : 1867 - 1872
  • [3] The effect of Daclizumab in a high-risk renal transplant population
    Meier-Kriesche, HU
    Kaza, H
    Palekar, SS
    Friedman, GS
    Mulgaonkar, SP
    Ojo, AO
    Kaplan, B
    CLINICAL TRANSPLANTATION, 2000, 14 (05) : 509 - 513
  • [4] Two-Dose Steroid Combined with Two-Dose Daclizumab and Tacrolimus Regimen in Liver Transplant Recipients
    Ju, Weiqiang
    He, Xiaoshun
    Wu, Linwei
    Guo, Zhiyong
    Wang, Dongping
    LIVER TRANSPLANTATION, 2010, 16 (06) : S230 - S230
  • [5] Mycophenolate mofetil with lower cyclosporine dose in high-risk renal transplant recipients
    Esmeraldo, RM
    Donadi, MORC
    Oliveira, ML
    Ponte, CN
    Pinheiro, PMA
    TRANSPLANTATION PROCEEDINGS, 1999, 31 (07) : 3007 - 3008
  • [6] Use of daclizumab (zenapax) as initial immunosupression in liver transplant recipients with kidney failure
    Emre, S
    Vanin, A
    Cervantes, E
    Heidt, D
    Fishbein, T
    Sheiner, P
    Schwartz, M
    Miller, C
    TRANSPLANTATION, 1999, 67 (09) : S600 - S600
  • [7] The safety and efficacy of a two-dose daclizumab (Zenapax) induction therapy in liver transplant patients
    Eckhoff, DE
    McGuire, B
    Sellers, M
    Contreras, J
    Frenette, L
    Hudson, S
    Ingram, C
    Bynon, S
    TRANSPLANTATION, 1999, 67 (07) : S32 - S32
  • [8] Zenapax versus OKT-3 prophylaxis in immunologically high-risk kidney transplant recipients
    Lácha, J
    Símová, M
    Nosková, L
    Teplan, V
    Vítko, S
    TRANSPLANTATION PROCEEDINGS, 2001, 33 (03) : 2273 - 2274
  • [9] Informed Consent in High-Risk Renal Transplant Recipients
    Cocchiara, G.
    Lo Monte, A. I.
    Romano, G.
    Romano, M.
    Buscemi, G.
    TRANSPLANTATION PROCEEDINGS, 2009, 41 (05) : 1524 - 1526
  • [10] The Efficacy of Rituximab in High-risk Renal Transplant Recipients
    Araki, Motoo
    Wada, Koichiro
    Mitsui, Yosuke
    Kubota, Risa
    Yoshioka, Takashi
    Ariyoshi, Yuichi
    Kobayashi, Yasuyuki
    Kitagawa, Masashi
    Tanabe, Katsuyuki
    Sugiyama, Hiroshi
    Wada, Jun
    Watanabe, Masami
    Watanabe, Toyohiko
    Hotta, Katsuyuki
    Nasu, Yasutomo
    ACTA MEDICA OKAYAMA, 2016, 70 (04) : 295 - 297
12345